Učitavanje...
The role of carfilzomib in relapsed/refractory multiple myeloma
Carfilzomib is the second proteasome inhibitor approved for relapsed multiple myeloma. Since its approval in 2012, carfilzomib has been an active and versatile drug, based on its efficacy as a single agent; superiority as a doublet with dexamethasone compared with bortezomib and dexamethasone; and a...
Spremljeno u:
| Izdano u: | Ther Adv Hematol |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
SAGE Publications
2021
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8191071/ https://ncbi.nlm.nih.gov/pubmed/34163580 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/20406207211019612 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|